Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BBM-L101 Injection in Participants With Limb-Girdle Muscular Dystrophy Type 2D/R3

NCT07874516 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07874516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BBM-L101 Injection in Participants With Limb-Girdle Muscular Dystrophy Type 2D/R3
Lead sponsor
Peking University First Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2032
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

limb girdle muscular dystrophy type 2d/r3